Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Phosphorylation of histone H2AX as a marker of dsDNA breaks induced from cell internalization of Dato-DΧd. A, TROP2-negative cell line END(K)34 does not show statistically significant difference in p-H2AX MFI when treated with 5 μg/mL Dato-DΧd vs. when treated with 5 μg/mL control ADC (P > 0.05). B and C, Increase in p-H2AX MFI is statistically significant when high (3+) TROP2-expressing cell lines END(K)254 and END(K)265 are treated with 5 μg/mL Dato-DΧd vs. 5 μg/mL control ADC (P = 0.0156 and P = 0.0427; *, P